Isoschaftoside improves white matter injury via TREM2-mediated phagocytosis and anti-inflammatory effects.
Experimental evidence is provided supporting ISO as a potential therapeutic agent for vascular cognitive impairment by dose-dependently improving cognitive function and attenuated demyelination in white matter regions of BCAS mice.